. 2017 Jul;9(Suppl 8):S697–S704. doi: 10.21037/jtd.2017.03.159

Table 1. Key trials in esophageal and esophagogastric junction tumours.

Trial	Tumour types (number of patients)	Treatment arms	pCR rate (%)	Median survival (months)	5 year survival (%)	Hazard ratio (95% confidence interval)
OE02 (4,8)	SCC [269]	Surgery	2	13	17	HR =0.84 (0.72–0.98)
OE02 (4,8)	Adeno [533]	Neoadjuvant Chemotherapy	4	17	23	HR =0.84 (0.72–0.98)
MAGIC (2)	Adeno [503]	Surgery	0	20	23	HR =0.75 (0.6–0.93)
MAGIC (2)	(junctional 26%)	Peri-operative chemotherapy	0	24	36	HR =0.75 (0.6–0.93)
ACCORD 07 FNCLCC-FFCD 9703 (3)	Adeno [224]	Surgery	0	Not reported	24	HR =0.69 (0.5–0.95)
ACCORD 07 FNCLCC-FFCD 9703 (3)	(Lower esophagus 11%, junctional 64%)	Peri-operative chemotherapy	3		38	HR =0.69 (0.5–0.95)
CROSS (1,5)	SCC [96]	Surgery	0	24	33	HR =0.67 (0.51–0.87)
CROSS (1,5)	Adeno [270]	Neoadjuvant chemoradiotherapy	29	49	47	HR =0.67 (0.51–0.87)